These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31630159)

  • 1. Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis.
    Rome BN; Kesselheim AS
    Clin Infect Dis; 2020 Oct; 71(7):1671-1675. PubMed ID: 31630159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.
    Kerr KW; Glos LJ
    Pharmaceut Med; 2020 Feb; 34(1):19-29. PubMed ID: 32048213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012-2018.
    Rome BN; Lee CC; Kesselheim AS
    Clin Pharmacol Ther; 2021 Feb; 109(2):367-371. PubMed ID: 32654122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers.
    Kesselheim AS; Rome BN; Sarpatwari A; Avorn J
    Health Aff (Millwood); 2017 Feb; 36(2):362-370. PubMed ID: 28100464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US.
    Padula WV; Parasrampuria S; Socal MP; Conti RM; Anderson GF
    Pharmacoeconomics; 2020 Oct; 38(10):1115-1121. PubMed ID: 32533523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modifying the Criteria for Granting Orphan Drug Market Exclusivity.
    Socal MP; Parasrampuria S; Anderson GF
    Value Health; 2020 Nov; 23(11):1470-1476. PubMed ID: 33127018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing Onset of Biosimilar Versus Generic Competition in the United States.
    Beall RF; Ronksley PE; Wick J; Darrow JJ; Sarpatwari A; Kesselheim AS
    Clin Pharmacol Ther; 2020 Dec; 108(6):1308-1314. PubMed ID: 32621540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Labeling Changes and Costs for Clinical Trials Performed Under the US Food and Drug Administration Pediatric Exclusivity Extension, 2007 to 2012.
    Sinha MS; Najafzadeh M; Rajasingh EK; Love J; Kesselheim AS
    JAMA Intern Med; 2018 Nov; 178(11):1458-1466. PubMed ID: 30264138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generic entry, reformulations and promotion of SSRIs in the US.
    Huskamp HA; Donohue JM; Koss C; Berndt ER; Frank RG
    Pharmacoeconomics; 2008; 26(7):603-16. PubMed ID: 18563951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated trends in US brand-name and generic drug competition.
    Grabowski H; Long G; Mortimer R; Boyo A
    J Med Econ; 2016 Sep; 19(9):836-44. PubMed ID: 27064194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring and Understanding Market Exclusivity Length for New Prescription Drugs in France, Australia, and the USA.
    Van de Wiele VL; Kesselheim AS; Gleeson D; Lu Z; Tu SS; Rome BN
    Pharmaceut Med; 2024 Jul; 38(4):303-310. PubMed ID: 39003670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Method for Approximating Future Entry of Generic Drugs.
    Beall RF; Darrow JJ; Kesselheim AS
    Value Health; 2018 Dec; 21(12):1382-1389. PubMed ID: 30502781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of Market Exclusivity for Prescription Drugs in the United States.
    Kesselheim AS; Sinha MS; Avorn J
    JAMA Intern Med; 2017 Nov; 177(11):1658-1664. PubMed ID: 28892528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuing trends in U.S. brand-name and generic drug competition.
    Grabowski H; Long G; Mortimer R; Bilginsoy M
    J Med Econ; 2021; 24(1):908-917. PubMed ID: 34253119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
    Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
    JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy.
    Outterson K; McDonnell A
    Health Aff (Millwood); 2016 May; 35(5):784-90. PubMed ID: 27140983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Market Exclusivity Time for Top Selling Originator Drugs in Canada: A Cohort Study.
    Lexchin J
    Value Health; 2017 Sep; 20(8):1139-1142. PubMed ID: 28964446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic return of clinical trials performed under the pediatric exclusivity program.
    Li JS; Eisenstein EL; Grabowski HG; Reid ED; Mangum B; Schulman KA; Goldsmith JV; Murphy MD; Califf RM; Benjamin DK
    JAMA; 2007 Feb; 297(5):480-8. PubMed ID: 17284698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.